newsfilter
← Latest News
GlobeNewswire·

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its